Global Bispecific Antibody Market, By Type (Immunoglobulin G (IgG) such as Molecule and Non Immunoglobulin G (IgG) such as Molecule), Mechanism of Action (Bispecific Diabodies and Bispecific T-Cell Engager Antibodies), Application (Oncology, Autoimmune Disease and Others), Drugs (Blinatumomab, Catumaxomab, Duligotumab and Others), Route of Administration (Oral and Injectable), End-Users (Hospitals, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies and Retail Pharmacies) – Industry Trends and Forecast to 2030.
Bispecific Antibody Market Analysis and Size
Major factors that are expected to boost the growth of the bispecific antibody market in the forecast period are the rise in the special designation from the regulatory authorities. Furthermore, the constant clinical trial conducted by several pharmaceuticals industries is further anticipated to propel the growth of the bispecific antibody market. On the other hand, the insufficient operating revenue prospects for the research and development of targeted therapies by numerous pharmaceuticals is further projected to impede the growth of the bispecific antibody market in the timeline period.
Data Bridge Market Research analyses that the bispecific antibody market which was USD 545 million in 2022, would rocket up to USD 1,782 million by 2030, and is expected to undergo a CAGR of 6.9% during the forecast period. This indicates that the market value. “Oncology” dominates the application segment of the bispecific antibody market owing to the increasing incidence of chronic diseases, such as cancer and autoimmune disorders. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Bispecific Antibody Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Immunoglobulin G (IgG) such as Molecule and Non Immunoglobulin G (IgG) such as Molecule), Mechanism of Action (Bispecific Diabodies and Bispecific T-Cell Engager Antibodies), Application (Oncology, Autoimmune Disease and Others), Drugs (Blinatumomab, Catumaxomab, Duligotumab and Others), Route of Administration (Oral and Injectable), End-Users (Hospitals, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies and Retail Pharmacies)
|
|
Countries Covered
|
U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, Rest of the Middle East and Africa
|
|
Market Players Covered
|
Adimab, Innovent Biologics, Inc (U.S.), Affimed GmbH (China), Amgen Inc (Germany), AstraZeneca (U.K.), Xencor (U.S.), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Regeneron Pharmaceuticals Inc (U.S.), Lilly (U.S.), Pieris Pharmaceuticals, Inc (U.S.), Mereo BioPharma Group plc (U.K), Sobi, TG Therapeutics Inc (Swden), Merus (Netherlands), MacroGenics, Inc (U.S.), Genmab A/S (Denmark), Emergent BioSolutions Inc (U.S.), Alteogen (South Korea), Astellas Pharma Inc (Japan), Novartis AG (Switzerland) and CELGENE CORPORATION (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Bispecific antibodies are considered artificial proteins in which two or more antigen distinguishing elements are mixed together to create a single construct. Bispecific antibodies are able to bind into two or more targets at the same time.
Bispecific Antibody Market Dynamics
Drivers
- Growing Prevalence of Chronic Diseases
The increasing incidence of chronic diseases, such as cancer and autoimmune disorders, is a major driver for the bispecific antibody market. Bispecific antibodies offer the potential for targeted therapies and improved treatment outcomes in these disease areas.
- Advancements in Biotechnology and Antibody Engineering
Technological advancements in biotechnology and antibody engineering have enabled the development of bispecific antibodies with enhanced specificity, potency, and pharmacokinetic properties. These advancements drive the growth and adoption of bispecific antibodies in therapeutic applications.
- Increasing Research and Development Activities
There is a significant focus on research and development of bispecific antibodies, both by pharmaceutical companies and academic institutions. This drives innovation, expands the pipeline of bispecific antibody candidates, and fuels market growth.
- Growing Demand for Personalized Medicine
The shift towards personalized medicine and precision therapeutics creates opportunities for bispecific antibodies. These antibodies can be designed to target specific biomarkers or pathways, allowing for tailored treatment approaches based on individual patient characteristics.
Opportunities
- Expanded Therapeutic Applications
Bispecific antibodies offer opportunities for therapeutic applications across a wide range of disease areas beyond oncology, including autoimmune disorders, infectious diseases, and cardiovascular diseases. Exploring new indications and expanding the therapeutic scope presents growth opportunities.
- Collaborations and Partnerships
Collaborations between pharmaceutical companies, academic institutions, and research organizations can facilitate the development and commercialization of bispecific antibodies. Partnerships and licensing agreements can leverage expertise, resources, and accelerate market penetration.
Restraints/Challenges
- Complex Manufacturing Processes
Bispecific antibody production involves intricate manufacturing processes, including specialized technologies and platforms. The complexity of manufacturing can pose challenges, impacting scalability, cost-effectiveness, and commercial viability.
- High Development Costs
The development of bispecific antibodies involves substantial investments in research, preclinical studies, and clinical trials. High development costs can act as a restraint, particularly for smaller biotechnology companies with limited financial resources.
- Immunogenicity Concerns
Bispecific antibodies can trigger immune responses, leading to the development of antidrug antibodies and potential loss of efficacy. Managing and mitigating immunogenicity concerns pose challenges in the development and clinical use of bispecific antibodies.
This bispecific antibody market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bispecific antibody market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In July 2022, Janssen Pharmaceutical reported announced that it has received conditional marketing authorisation for Teclistamab in patients with multiple myeloma from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). In addition, the business has submitted a Biologics Licence Application (BLA) to the US FDA in order to get clearance for its innovative medications. The approval is based on the favourable findings of a late-stage clinical trial that recommended increasing the drug's survival rates. The medicine is projected to be accessible in the market by the end of 2022, under the brand name Tecvalyi. Panther Healthcare launched the Smart Powered Stapler platform, which provides intelligent and automated control of tissue fixation, transection and resection across gastrointestinal (including bariatric), thoracic, colorectal, oncology, gynecology and other open and laparoscopic surgical procedures. The device was released in Europe, the Middle East, Africa, Asia and Latin America.
- In August 2018, an scientific research company based in Belgium i.e UCB pharma conducted a research on molecular factors in bispecific antibody multimerisation and revealed that the monomer level of single-chain variable fragment containing bispecific antibody format can be increased by conversion of the single chain variable to a disulfide- stabilized single chain variable fragment. through more uniform tissue compression and better stapling.
Global Bispecific Antibody Market Scope
The bispecific antibody market is segmented on the basis of type, mechanism of action, application, drugs, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets
Type
- Immunoglobulin G (IgG) such as Molecule
- Non Immunoglobulin G (IgG) such as Molecule
Mechanism of Action
- Bispecific Diabodies
- Bispecific T-Cell Engager Antibodies
Application
- Oncology
- Autoimmune Disease
- Others
Drugs
- Blinatumomab
- Catumaxomab
- Duligotumab
- Others
Route of Administration
- Oral
- Injectable
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
Bispecific Antibody Market Regional Analysis/Insights
The bispecific antibody market is analyzed, and market size information is provided by type, mechanism of action, application, drugs, route of administration, end-users and distribution channel as referenced above.
The countries covered in the bispecific antibody market report are the U.S., Canada, and Mexico in North America, Peru, Brazil, Argentina, and the rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA)
North America dominates the bispecific antibody market due to the occurrence of major key players. Furthermore, the highest numbers of several cancers such as lung cancer, prostate cancer, breast cancer and cervical cancer will further boost the growth of the bispecific antibody market in the region during the forecast period. Asia-Pacific is projected to observe significant amount of growth of the bispecific antibody market due to the shortage of good healthcare facilities in the several countries. Moreover, the wide rise in the healthcare infrastructure like healthcare expenses, healthcare facility and health care budget and the increase in the penetration is further anticipated to propel the growth of the bispecific antibody market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Bispecific Antibody Market Share Analysis
The bispecific antibody market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to bispecific antibody market.
Some of the major players operating in the bispecific antibody market are:
- Adimab, Innovent Biologics, Inc (U.S.)
- Affimed GmbH (China)
- Amgen Inc (Germany
- AstraZeneca (U.K.)
- Xencor (U.S.)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Regeneron Pharmaceuticals Inc (U.S.)
- Eli Lilly (U.S.)
- Pieris Pharmaceuticals, Inc (U.S.)
- Mereo BioPharma Group plc (U.K)
- Sobi, TG Therapeutics Inc (Swden)
- Merus (Netherlands)
- MacroGenics, Inc (U.S.)
- Genmab A/S (Denmark)
- Emergent BioSolutions Inc (U.S.)
- Alteogen (South Korea)
- Astellas Pharma Inc (Japan)
- Novartis AG (Switzerland)
- CELGENE CORPORATION (U.S.)
SKU-